BWIN · Baldwin Insurance Group

The thesis

The Baldwin Insurance Group is under a signed $32.50-per-share cash take-private, so the shares have little room to rise above the agreed price and are more likely to lag the S&P 500 than lead it. The shareholder vote, the antitrust waiting period and the buyers' debt financing decide the outcome. The company targets a first-quarter 2027 close.

The shares closed at $32.04 on 11 November 2026, below the $32.50 cash price. The market is pricing a high chance that the deal completes, with a small discount for the months to closing and the risk that it breaks.

The newest facts are the third-quarter Form 10-Q and the final results release, both filed 9 November 2026. They confirm revenue of $480.26 million and a net loss of $81.6 million, the same as the preliminary figures released on 27 October 2026. Those results matter as the fallback value if the merger fails. While the deal stands, the price follows deal progress.

The rating is Low because the cash price caps the upside and no competing bid had been reported as of 11 November 2026.

Bullish and bearish views on The Baldwin Insurance Group, Inc.

The bull case on The Baldwin Insurance Group, Inc. (BWIN), in brief: cash price is signed and board-approved. The bear case: upside is capped at the agreed price.

Bull case

• Cash price is signed and board-approved. The 14 September 2026 merger agreement pays $32.50 in cash per eligible share. The board approved it unanimously on the unanimous recommendation of a special committee of independent directors. The company puts the enterprise value at approximately $7.7 billion. Insurance Business reported on 28 October 2026 that the price is an 88% premium to the unaffected close of 17 June 2026.
• Financing is not a closing condition. Finimize, citing Bloomberg, reported that Morgan Stanley launched about $2.3 billion of buyout loans on 3 November 2026. Early price talk reported on 4 November 2026 put the term loan at about 3.5 percentage points over the floating benchmark rate, offered at 99 cents on the dollar. Completion does not depend on the buyers obtaining financing.
• The vote looks narrow. Holders of a majority of the Class B shares delivered written consent on 14 September 2026. The preliminary proxy says approval needs a majority of the combined Class A and Class B voting power and calls this the only stockholder vote required.
• Operating results held up in the third quarter. The 9 November 2026 results release shows organic revenue growth of 6%. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, as adjusted) rose 47% to $106.9 million, a 22.2% margin against 19.8% a year earlier. Adjusted diluted EPS (earnings per share) rose 35% to $0.42, and adjusted free cash flow rose 33% to $55.6 million.

Bear case

• Upside is capped at the agreed price. The merger agreement's no-shop covenant allows the board to consider only unsolicited superior proposals. The preliminary proxy sets a company termination fee of $170,334,000. No competing bid had been reported as of 11 November 2026.
• Approvals and timetable are still open. The amended preliminary proxy filed in October 2026 leaves the special meeting date and record date blank. It lists expiry or termination of the Hart-Scott-Rodino antitrust waiting period as a closing condition and gives no status. The 9 November 2026 results release repeats the first-quarter 2027 target without a vote date.
• Reported losses widened. The third-quarter net loss was $81.6 million against $30.2 million a year earlier, or $0.63 per diluted share, per the 9 November 2026 release. The quarter carried $21.0 million of go-private transaction costs. Insurance Business reported on 28 October 2026 that nine-month organic growth slowed to 3% from 9% a year earlier.
• Revenue missed the company's own range. Third-quarter revenue of $480.3 million sat below the $485–495 million guidance given on 30 July 2026. The 9 November 2026 release gives no new guidance.
• Debt is heavy before the buyout loans. At 30 September 2026 the company carried $2,148.0 million of long-term debt less the current portion, $272.0 million drawn on its revolving credit line and $188.6 million of cash, per the results release. Insurance Business reported third-quarter net interest expense of $43.6 million, up from $32 million a year earlier.

Price setup

The shares closed at $32.04 on 11 November 2026. The 52-week intraday high is $32.70 on 15 September 2026, the first session after the deal announcement and above the cash price. The last close sits 2.0% below that high.

Closes from 4 November to 11 November 2026 ranged between $31.97 and $32.18. That narrow range is typical of a stock held near a fixed cash price. The 50-day moving average was $31.66 and the 200-day moving average $25.34 as of 11 November 2026. The 200-day average still includes months of trading before the bid.

The shares are up 3.9% over three months, from a close of $30.85 on 13 August 2026. The 52-week closing low is $16.50 on 13 February 2026, which shows where the stock traded on its own before buyer interest. A break in the deal would point the shares back toward stand-alone value. Deal news, rather than earnings, moves the price.

Catalysts ahead

• Undated: Definitive proxy statement and special meeting date. The amended preliminary proxy leaves the meeting and record dates blank; the definitive filing sets the vote timetable for a first-quarter 2027 close.
• Undated: Hart-Scott-Rodino antitrust waiting-period expiry or termination. It is a closing condition, and company filings have not yet disclosed its status; clearance removes one of the open approvals.
• Undated: Final pricing and allocation of the $2.3 billion buyout loans. Final terms show whether lenders absorb the debt that funds part of the $32.50 cash price at the early price talk or demand more.
• Q1 2027 (est.): Targeted completion of the $32.50 cash merger. Completion pays holders $32.50 per share and ends public trading; a slip past the quarter extends the time to payment.
• ~14 June 2027 (outside date): Initial end date of the merger agreement, extendable to 14 September 2027. If the deal has not closed by then, either side may gain termination rights, which would expose the shares to stand-alone value.

What would change the view

A daily close above $36.53, a level the shares would reach only on a competing or raised offer above the $32.50 cash price, which would show them leading the S&P 500; a filed superior proposal or an increased merger price would also prove the call wrong.

What it trades with

The shares trade on deal probability and the time left to a first-quarter 2027 close. Peer insurance brokers react to organic growth and commercial insurance pricing, and Baldwin's price is anchored by the $32.50 cash offer instead. Moves in the S&P 500 matter little unless credit markets weaken enough to disrupt the $2.3 billion loan syndication or the buyers' financing. In a broad market rally the shares cannot follow above the cash price, so they tend to lag in rising markets and hold up in falling ones while the deal stands.